Kim Jiwon, Noh Woojeong, Kim Ahrim, Choi Yoomin, Kim Young-Sik
College of Korean Medicine, Woosuk University, Jeonju 54986, Republic of Korea.
Department of Acupuncture & Moxibustion Medicine, College of Korean Medicine, Woosuk University, Jeonju 54986, Republic of Korea.
Int J Mol Sci. 2023 Sep 12;24(18):13999. doi: 10.3390/ijms241813999.
Fenugreek is a widely used herbal medicine as a complementary therapy for diabetes mellitus. Lots of clinical trials have proved its beneficial effect on glycemic control parameters and lipid profiles. Thus, we conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of fenugreek as a treatment for type 2 diabetes mellitus. We searched PubMed, Embase, Cochrane, China Knowledge Resource Integrated Database (CNKI), Korean studies Information Service System (KISS), Research Information Sharing Service (RISS), and ScienceON to select RCTs which used fenugreek targeting hyperglycemia with a control group. We used either a random effect model or a fixed model in a meta-analysis of Fasting blood glucose (FBG), 2 h plasma glucose during a 75 g oral glucose tolerance test (OGTT) (2-hPG), homeostatic model assessment for insulin resistance (HOMA-IR), glycosylated hemoglobin (HbA1c)/total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), body mass index (BMI). After screening, a total of 10 studies (706 participants) remained. Fenugreek significantly reduced FBG, 2-hPG, and HbA1c, but it did not significantly decrease HOMA-IR. Moreover, it significantly improved TC, TG, and HDL-C, while there were no significant differences in LDL-C and BMI. Hepatic or renal toxicity was not observed, and there were no severe adverse events associated with fenugreek despite mild gastrointestinal side effects in some studies. In conclusion, fenugreek improves overall glycemic control parameters and lipid profile safely.
胡芦巴是一种广泛使用的草药，作为糖尿病的辅助治疗方法。大量临床试验已证明其对血糖控制参数和血脂谱有有益作用。因此，我们进行了一项系统评价和荟萃分析，以评估胡芦巴治疗2型糖尿病的有效性和安全性。我们检索了PubMed、Embase、Cochrane、中国知网（CNKI）、韩国研究信息服务系统（KISS）、研究信息共享服务（RISS）和ScienceON，以选择使用胡芦巴针对高血糖且设有对照组的随机对照试验（RCT）。在对空腹血糖（FBG）、75克口服葡萄糖耐量试验（OGTT）期间的2小时血浆葡萄糖（2-hPG）、胰岛素抵抗的稳态模型评估（HOMA-IR）、糖化血红蛋白（HbA1c）/总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）、体重指数（BMI）进行荟萃分析时，我们使用了随机效应模型或固定模型。筛选后，共保留了10项研究（706名参与者）。胡芦巴显著降低了FBG、2-hPG和HbA1c，但未显著降低HOMA-IR。此外，它显著改善了TC、TG和HDL-C，而LDL-C和BMI没有显著差异。未观察到肝毒性或肾毒性，尽管在一些研究中有轻微的胃肠道副作用，但未发现与胡芦巴相关的严重不良事件。总之，胡芦巴能安全地改善整体血糖控制参数和血脂谱。
